Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma

References

• Facts SCS. 2018. Hodgkin lymphoma. National Cancer Institute; [cited 2018 Nov 25]. Available from: https://seer.cancer.gov/statfacts/html/hodg.html
   Google Scholar
• Facts SCS. 2018. Non-Hodgkin lymphoma. National Cancer Institute; [cited 2018 Nov 24]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html
   Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.
   PubMed Web of Science ®Google Scholar
• Crump MN, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2018;131:587–588.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31–46.
   PubMed Web of Science ®Google Scholar
• Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.
   PubMed Web of Science ®Google Scholar
• Ghobadi A. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. Curr Res Transl Med. 2018;66:43–49.
   PubMed Web of Science ®Google Scholar
• Davenport AJ, Cross RS, Watson KA, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci USA. 2018;115:E2068–E2076.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285–295.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545–2554.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2017;130:577.
   Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8:355ra116.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose-finding and definition of pivotal cohort. Blood. 2017;130:581.
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
   PubMed Web of Science ®Google Scholar
• FDA. 2017 Oct 25. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. [cited 2018 Nov 25]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm581296.htm
   Google Scholar
• FDA. 2018 May 5. FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma. [cited 2018 Nov 25]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm
   Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–638.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
   PubMed Web of Science ®Google Scholar
• Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:35.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute; [cited 2019 Jul 27]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–3330.
   PubMed Web of Science ®Google Scholar
• Perica K, Flynn J, Curran KJ, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. J Clin Oncol. 2019;37:2520–2520.
   Web of Science ®Google Scholar
• Sim AJ, Jain MD, Figura NB, et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2019. DOI:10.1016/j.ijrobp.2019.05.065
   PubMed Web of Science ®Google Scholar
• Smith SD, Reddy P, Sokolova A, et al. Eligibility for Car T-cell therapy: an analysis of selection criteria and survival outcomes in chemorefractory DLBCL. Am J Hematol. 2019;94:E117.
   PubMed Web of Science ®Google Scholar
• Nastoupil LJ, Jain MD, Spiegel JY, et al. 2018. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. ASH; [cited 2018 Dec 15]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper114152.html
   Google Scholar
• Jacobson CA, Hunter B, Armand P, et al. 2018. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. ASH; [2018 Dec 15]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper117199.html
   Google Scholar
• Sano D, Nastoupil LJ, Fowler NH, et al. 2018. Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma. [cited 2018 Dec 15]. Available from: https://ash.confex.com/ash/2018/webprogram/Paper120013.html
   Google Scholar
• Pasquini M. Real world experience of tisagenlecleucel chimeric antigen receptor (CAR) T-cells targeting CD19 in patients with acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Annual Meeting; 2019. Houston (TX): SOHO; 2019.
   Google Scholar
• Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133:2212–2221.
   PubMed Web of Science ®Google Scholar
• Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131:121–130.
   PubMed Web of Science ®Google Scholar
• Strati P, Nastoupil LJ, Fayad LE, et al. Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection. Blood. 2019;133:2800–2802.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Irwin KE, Frigault MJ, et al. Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer. 2019;125:3692–3698.
   PubMed Web of Science ®Google Scholar
• Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017;377:783–784.
   PubMed Web of Science ®Google Scholar
• Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR-T cell therapy in secondary CNS lymphoma. Blood. 2019;134:860.
   PubMed Web of Science ®Google Scholar
• McGuirk J, Waller EK, Qayed M, et al. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy. 2017;19:1015–1024.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182:633–643.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919.
   PubMed Web of Science ®Google Scholar
• Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120:4256–4262.
   PubMed Web of Science ®Google Scholar
• Locke FLG, Lekakis A, Miklos LJ, et al. Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma. J Clin Oncol. 2018;36:3039–3039.
   Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Matasar MJ, Meikle J, et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015;125:2579–2581.
   PubMed Web of Science ®Google Scholar
• Armand P, Welch S, Kim HT, et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013;160:608–617.
   PubMed Web of Science ®Google Scholar
• Zelenetz A, Gordon L, Abramson J, et al. NCCN clinical practice guidelines in oncology. B-cell lymphomas Version 3.2019. J Natl Compr Canc Netw. 2019;17:650–661.
   Google Scholar